Generic Name: olopatadine ophthalmic

Brand Names: Pataday, Patanol

Uses

Allergic Conjunctivitis

Temporary prevention of ocular itching associated with allergic conjunctivitis.

Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution. Not for injection or oral use.

If more than one topical ophthalmic drug is used, administer the drugs at least 5 minutes apart.

Avoid contamination of the solution container.

Dosage

Available as olopatadine hydrochloride; dosage expressed in terms of olopatadine.

Pediatric Patients

Allergic Conjunctivitis

Ophthalmic

Children ≥3 years of age: 1 or 2 drops of a 0.1% solution in the affected eye(s) twice daily (at an interval of 6–8 hours).

Once symptomatic improvement is established, continue therapy for as long as necessary to sustain improvement.

Adults

Allergic Conjunctivitis

Ophthalmic

1 or 2 drops of a 0.1% solution in the affected eye(s) twice daily (at an interval of 6–8 hours).

Once symptomatic improvement is established, continue therapy for as long as necessary to sustain improvement.

Cautions

Contraindications

• Known hypersensitivity to olopatadine or any ingredient in the formulation.

Warnings/Precautions

Specific Populations

Pregnancy

Category C.

Lactation

Distributed into milk in rats following oral administration; not known whether distributed into human milk following topical application to the eye. Use with caution.

Pediatric Use

Safety and efficacy not established in children <3 years of age.

Appears to be well-tolerated in children 3–16 years of age.

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.

Common Adverse Effects

Headache.

Interactions

No formal drug interaction studies to date.

Pharmacokinetics

Absorption

Bioavailability

Limited systemic exposure following topical application to the eye; plasma concentrations usually are undetectable.

Onset

Rapid onset; symptomatic relief of itching generally occurs within 30 minutes.

Duration

Long duration (≥8 hours).

Distribution

Extent

Distribution into human ocular tissues and fluids not characterized.

Elimination

Metabolism

Metabolized in the liver to monodesmethyl olopatadine and olopatadine N-oxide following topical application to the eyes.

Elimination Route

Eliminated principally by renal excretion; 60–70% of systemically absorbed dose excreted in urine as parent drug.

Half-life

Approximately 3 hours following topical application to the eyes.

Stability

Storage

Ophthalmic

Solution

4–25°C.

Actions

• Inhibits type I immediate hypersensitivity reactions in vitro and in vivo.
• Suppresses the release of inflammatory mediators (e.g., histamine, prostaglandin D₂, tryptase) in response to antigenic stimulation of human conjunctival mast cells in a dose-dependent manner.
• Inhibits histamine-stimulated conjunctival vascular permeability response in a concentration-dependent manner.
• Potency is comparable to that of levocabastine and exceeds that of pheniramine or antazoline.

Advice to Patients

• Importance of learning and adhering to proper administration techniques to avoid contamination of the solution container.
• Importance of removing soft contact lenses prior to administration of each dose. Delay reinsertion for 10 minutes after administration if eyes are not red; do not wear contact lenses if eye(s) are red. Not indicated for contact lens-related irritation.
• Importance of administering different topical ophthalmic preparations at least 5 minutes apart.
• Importance of patients informing clinicians of exisiting or contemplated therapy, including prescription and OTC drugs.
• Importance of women informing clinicians if they are or plan to become pregnant or to breast-feed.
• Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 09/2009. For the most current and up-to-date pricing information, please visit www.drugstore.com. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

AHFS Drug Information. © Copyright, 1959-2009, Selected Revisions May 2004. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.